Similar articles for PMID: 28546335

Year	Number of Results
1996	1
1997	1
1998	2
1999	1
2000	3
2001	2
2002	3
2003	2
2004	1
2005	1
2006	1
2007	5
2008	2
2009	1
2010	4
2011	4
2012	3
2013	1
2014	7
2015	4
2016	7
2017	5
2018	6
2019	5
2020	8
2021	14
2022	10
2023	7
2024	3

1

Le D. Le D. J Nucl Med. 2017 May 25:jnumed.117.196568. doi: 10.2967/jnumed.117.196568. Online ahead of print. J Nucl Med. 2017. PMID: 28546335 Free article. No abstract available.

2

[Development of bifunctional radiopharmaceuticals for targeted imaging and therapy].

Mukai T. Mukai T. Yakugaku Zasshi. 2007 Dec;127(12):1937-45. doi: 10.1248/yakushi.127.1937. Yakugaku Zasshi. 2007. PMID: 18057782 Free article. Review. Japanese.

3

Aptamers as radiopharmaceuticals for nuclear imaging and therapy.

Gijs M, Aerts A, Impens N, Baatout S, Luxen A. Gijs M, et al. Nucl Med Biol. 2016 Apr;43(4):253-71. doi: 10.1016/j.nucmedbio.2015.09.005. Epub 2015 Sep 28. Nucl Med Biol. 2016. PMID: 26746572 Review.

4

Radiopharmaceuticals in the elderly cancer patient: Practical considerations, with a focus on prostate cancer therapy: A position paper from the International Society of Geriatric Oncology Task Force.

Prior JO, Gillessen S, Wirth M, Dale W, Aapro M, Oyen WJG. Prior JO, et al. Eur J Cancer. 2017 May;77:127-139. doi: 10.1016/j.ejca.2017.01.030. Epub 2017 Apr 7. Eur J Cancer. 2017. PMID: 28391026 Free article.

5

Inspired by novel radiopharmaceuticals: Rush hour of nuclear medicine.

Liu Y, Ren YN, Cui Y, Liu S, Yang Z, Zhu H, Li N. Liu Y, et al. Chin J Cancer Res. 2023 Oct 30;35(5):470-482. doi: 10.21147/j.issn.1000-9604.2023.05.05. Chin J Cancer Res. 2023. PMID: 37969954 Free PMC article.

6

Biological carrier molecules of radiopharmaceuticals for molecular cancer imaging and targeted cancer therapy.

Aerts A, Impens NR, Gijs M, D'Huyvetter M, Vanmarcke H, Ponsard B, Lahoutte T, Luxen A, Baatout S. Aerts A, et al. Curr Pharm Des. 2014;20(32):5218-44. doi: 10.2174/1381612819666140110114902. Curr Pharm Des. 2014. PMID: 24606796 Review.

7

Comparative studies on the potential use of ¹⁷⁷Lu-based radiopharmaceuticals for the palliative therapy of bone metastases.

Zakaly HMH, Mostafa MYA, Deryabina D, Zhukovsky M. Zakaly HMH, et al. Int J Radiat Biol. 2020 Jun;96(6):779-789. doi: 10.1080/09553002.2020.1729441. Epub 2020 Mar 3. Int J Radiat Biol. 2020. PMID: 32043915

8

Evolving Role of Radiopharmaceuticals in Hepatocellular Carcinoma Treatment.

Wu L, Shen F, Xia Y, Yang YF. Wu L, et al. Anticancer Agents Med Chem. 2016;16(9):1155-65. doi: 10.2174/1871520616666160310143148. Anticancer Agents Med Chem. 2016. PMID: 26961314 Review.

9

The bright future of radionuclides for cancer therapy.

Nijsen JF, Krijger GC, van Het Schip AD. Nijsen JF, et al. Anticancer Agents Med Chem. 2007 May;7(3):271-90. doi: 10.2174/187152007780618207. Anticancer Agents Med Chem. 2007. PMID: 17504155 Review.

10

Radiopharmaceuticals for the Diagnosis and Therapy of Neuroendocrine Differentiated Prostate Cancer.

Giovacchini G, Giovannini E, Riondato M, Ciarmiello A. Giovacchini G, et al. Curr Radiopharm. 2017;10(1):6-15. doi: 10.2174/1874471009666161229123126. Curr Radiopharm. 2017. PMID: 28034291 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

101 results

Results by year